

10/771,254

**Amendments to the Claims:**

1. (Original) A stable formulation of Apo-2 ligand, comprising Apo-2 ligand and about 0.2M to about 0.5M salt, wherein said formulation has a pH of about 6 to about 9.
2. (Original) The formulation of claim 1 wherein said salt is arginine salt.
3. (Original) The formulation of claim 2 wherein the concentration of said arginine salt in the formulation is about 0.4M to about 0.5 M.
4. (Original) The formulation of claim 2 wherein the arginine salt is selected from the group consisting of arginine succinate, arginine sulphate, arginine malate, arginine citrate, arginine tartrate, and arginine phosphate.
5. (Original) The formulation of claim 2 wherein the arginine salt is arginine succinate.
6. (Original) The formulation of claim 1 wherein the salt is sodium sulphate.
7. (Original) The formulation of claim 1 or 6 wherein the Apo-2 ligand comprises crystallized protein.
8. (Original) The formulation of claim 1 wherein said formulation is lyophilized.
9. (Original) The formulation of claim 1 wherein the pH of said formulation is about 6.5 to about 8.5.
10. (Original) The formulation of claim 9 wherein the pH of said formulation is about 7 to about 7.5.
11. (Original) The formulation of claim 1 wherein the concentration of Apo-2 ligand is about 1 mg/ml to about 20 mg/ml.
12. (Original) The formulation of claim 1 wherein said Apo-2 ligand comprises amino acids 114 to 281 of Figure 1.
13. (Original) The formulation of claim 12 wherein said Apo-2 ligand is not linked or fused to an epitope tag.
14. (Original) The formulation of claim 1 wherein said formulation further comprises surfactant.

10/771,254

- 15. (Original) The formulation of claim 14 wherein said surfactant is a polysorbate or poloxamer.
- 16. (Original) The formulation of claim 14 wherein the concentration of said surfactant in the formulation is about 0.005% to about 0.2%.
- 17. (Original) The formulation of claim 1 wherein said formulation further comprises buffer.
- 18. (Original) The formulation of claim 17 wherein said buffer is Tris buffer.
- 19. (Original) The formulation of claim 18 wherein the pH of the formulation is about 7 to about 7.5.
- 20. (Original) The formulation of claim 1 wherein said formulation further comprises one or more divalent metal ions.
- 21. (Original) The formulation of claim 20 wherein said one or more divalent metal ions is zinc.
- 22. (Original) The formulation of claim 1 further comprising a preservative.
- 23. (Original) The formulation of claim 1 wherein said formulation is storage-stable for at least 12 months.
- 24. (Original) The formulation of claim 23 wherein said formulation is storage-stable for at least 24 months.
- 25. (Original) A stable, lyophilized formulation of Apo-2 ligand, comprising about 1 mg/ml to about 20 mg/ml Apo-2 ligand, about 0.2 M to about 0.5M arginine salt, buffer, and surfactant, wherein said formulation has a pH of about 6 to about 9.
- 26. (Original) The formulation of claim 25, wherein said arginine salt is arginine succinate.
- 27. (Original) The formulation of claim 26, wherein the concentration of said arginine succinate is about 0.4M to about 0.5M.
- 28. (Original) The formulation of claim 25, wherein said buffer is Tris buffer.
- 29. (Original) The formulation of claim 25, wherein said surfactant is a polysorbate.
- 30. (Original) The formulation of claim 25, wherein said Apo-2 ligand comprises amino acids 114 to 281 of Figure 1.

10/771,254

31. (Original) The formulation of claim 25, wherein said formulation further comprises one or more divalent metal ions.

32. (Original) A stable formulation of Apo-2 ligand, comprising about 1mg/ml to about 20 mg/ml Apo-2 ligand, about 0.2M to about 0.5 M salt, buffer, and surfactant, wherein said Apo-2 ligand comprises crystallized protein and said formulation has a pH of about 6 to about 9.

33. (Original) The formulation of claim 32, wherein said salt is sodium sulphate.

34. (Original) The formulation of claim 32, wherein said buffer is Tris buffer.

35. (Original) The formulation of claim 32, wherein said surfactant is polysorbate.

36. (Original) The formulation of claim 32, wherein said formulation has a pH of about 7 to about 7.5.

37. (Original) A stable formulation of Apo-2 ligand, comprising about 0.1 mg/ml to about 2 mg/ml Apo-2 ligand, sugar, and surfactant, wherein said formulation has a pH of about 6 to about 9.

38. (Original) The formulation of claim 37 wherein said sugar is trehalose.

39. (Original) The formulation of claim 37 wherein the concentration of the sugar in the formulation is about 1% to about 8%.

40. (Original) The formulation of claim 37 wherein said formulation is lyophilized.

Claims 41-72 (cancelled)